文献速递急性肾损伤慢性肾脏病

烟酰胺腺嘌呤二核苷酸缺乏在急性与慢性肾脏病中的差异作用

Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

研究分析人肾活检和小鼠模型,发现NAD+从头合成在急性肾损伤和慢性肾脏病中均受损,但烟酰胺核糖补充仅对缺血性急性肾损伤有益,对慢性肾脏病进展无效。

要点

  • NAD+从头合成在急性肾损伤和慢性肾脏病中均受损。
  • 烟酰胺核糖补充可预防缺血性急性肾损伤。
  • 烟酰胺核糖补充不能阻止慢性肾脏病进展。

核心结论

  • NAD+合成受损是急性肾损伤和慢性肾脏病的标志。
  • 烟酰胺核糖补充对缺血性急性肾损伤有益,但对慢性肾脏病模型无效。

研究设计与样本

  • 研究人同种异体肾移植患者和不同分期慢性肾脏病患者的肾活检。
  • 使用缺血再灌注损伤和顺铂注射模型模拟急性肾损伤。
  • 使用单侧输尿管梗阻和蛋白尿诱导的肾小管间质纤维化模型研究慢性肾脏病。
  • 在动物模型中评估烟酰胺核糖补充对急性肾损伤和慢性肾脏病的影响。

主要发现

  • 人肾移植活检再灌注期RNA测序显示NAD+从头合成受损,补救途径受刺激。
  • 两种缺血再灌注损伤小鼠模型中烟酰胺核糖补充预防血浆尿素和肌酐升高及肾小管损伤。
  • 慢性肾脏病患者活检中NAD+从头合成途径受损程度与分期相关,补救途径保存较好。
  • 单侧输尿管梗阻或慢性蛋白尿性肾小球疾病小鼠中观察到类似基因表达改变。
  • 烟酰胺核糖补充未预防慢性肾脏病进展,与急性肾损伤中的疗效相反。

临床怎么用

  • 烟酰胺核糖补充可能用于缺血性急性肾损伤的防治。
  • 慢性肾脏病中NAD+缺乏机制不同,烟酰胺核糖补充无效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous coenzyme involved in electron transport and a co-substrate for sirtuin function. NAD+ deficiency has been demonstrated in the context of acute kidney injury (AKI). METHODS: We studied the expression of key NAD+ biosynthesis enzymes in kidney biopsies from human allograft patients and patients with chronic kidney disease (CKD) at different stages. We used ischaemia-reperfusion injury (IRI) and cisplatin injection to model AKI, urinary tract obstruction [unilateral ureteral obstruction (UUO)] and tubulointerstitial fibrosis induced by proteinuria to investigate CKD in mice. We assessed the effect of nicotinamide riboside (NR) supplementation on AKI and CKD in animal models. RESULTS: RNA sequencing analysis of human kidney allograft biopsies during the reperfusion phase showed that the NAD+de novo synthesis is impaired in the immediate post-transplantation period, whereas the salvage pathway is stimulated. This decrease in de novo NAD+ synthesis was confirmed in two mouse models of IRI where NR supplementation prevented plasma urea and creatinine elevation and tubular injury. In human biopsies from CKD patients, the NAD+de novo synthesis pathway was impaired according to CKD stage, with better preservation of the salvage pathway. Similar alterations in gene expression were observed in mice with UUO or chronic proteinuric glomerular disease. NR supplementation did not prevent CKD progression, in contrast to its efficacy in AKI. CONCLUSION: Impairment of NAD+ synthesis is a hallmark of AKI and CKD. NR supplementation is beneficial in ischaemic AKI but not in CKD models.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Faivre A, Katsyuba E, Verissimo T, et al. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease. Nephrol Dial Transplant. 2021. PMID: 33099633. doi:10.1093/ndt/gfaa124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。